FDA warning on Samsca and potentially fatal liver injury

The FDA and Otsuka issued a warning to patients taking Samsca (tolvaptan) could potentially cause irreversible and fatal liver injury. The FDA recommends that healthcare
providers perform liver tests in patients exhibiting fatigue, anorexia, dark urine, jaundice or right upper abdominal discomfort. Samsca is a drug prescribed for treatment of hyperolemic and euvolemic hyponatremia.

If you or a loved one suspect liver damage from taking Samsca, please contact the experienced, ethical attorneys at the Ruth Law Team. 1-888-783-8378.